Drug executives: Big jump in vaccine supply is coming soon

WASHINGTON — COVID-19 vaccine makers told Congress on Tuesday to expect a big jump in the delivery of doses over the coming month, and the companies insist they will be able to provide enough for most Americans to get inoculated by summer.

By the end of March, Pfizer and Moderna expect to have provided the U.S. government with a total of 220 million vaccine doses, up sharply from the roughly 75 million shipped so far.

“We do believe we’re on track,” Moderna President Stephen Hoge said, outlining ways the company has ramped up production. “We think we’re at a very good spot.” Continue reading.

FDA authorizes Moderna’s COVID-19 vaccine for emergency use

Axios logo

The Food and Drug Administration has issued an emergency use authorization (EUA) for Moderna’s COVID-19 vaccine, one day after it was endorsed by a panel of independent experts.

Why it matters: The authorization of a second coronavirus vaccine, coming exactly one week after the FDA cleared Pfizer-BioNTech’s vaccine for emergency use, increases vaccine access for millions of Americans and marks another milestone on the country’s path to curbing the pandemic.

Between the lines: Moderna’s vaccine, which the FDA confirmed is safe and has a 94.1% efficacy rate, does not need to be stored at ultracold temperatures and comes in smaller batches, making it easier to distribute to rural areas than Pfizer’s vaccine.

FDA review clears path for second coronavirus vaccine, this one developed by Moderna

Washington Post logo

NOTE: This article is provided free of charge by the Washington Post.

Regulators, who confirmed the vaccine was 94 percent effective and raised no serious safety concerns, could authorize it as early as Friday

By the end of the week, the United States could have two coronavirus vaccines.

A vaccine developed by biotechnology company Moderna appears poised for regulatory clearance after a detailed data review by Food and Drug Administration scientists confirmed the two-shot regimen was “highly effective” in a clinical trial and carried no serious safety concerns.

The FDA is likely to authorize the Moderna vaccine as soon as Friday, according to a person with knowledge of the situation who spoke on the condition of anonymity because they were not authorized to discuss the issue. Anticipating that decision shortly, Gen. Gustave Perna, who is overseeing the federal effort to distribute vaccines, said Monday that the United States was preparing to ship almost 6 million doses of the Moderna vaccines to 3,285 locations in the first week.

What you need to know about the Moderna and Pfizer coronavirus vaccines

Washington Post logo

NOTE: This article is provided to readers free of charge by The Washington Post.

Both appear to be more than 90 percent effective in clinical trials and could begin to be available before the end of the year.

The vaccines are made by different companies: One is being developed by pharmaceutical giant Pfizer and its German partner, BioNTech, and the other by biotechnology firm Moderna, in partnership with the National Institute of Allergy and Infectious Diseases. Both drugmakers have moved at record speed and will seek regulatory clearance for their vaccines in the coming weeks.

Continue reading.